Companies in the Consumer Goods sector have received a lot of coverage today as analysts weigh in on Williams-Sonoma (WSM – Research Report) and Kohl’s (KSS – Research Report).
Williams-Sonoma (WSM)
Robert W. Baird analyst Peter Benedict maintained a Hold rating on Williams-Sonoma on November 17 and set a price target of $140.00. The company’s shares closed last Friday at $122.37.
According to TipRanks.com, Benedict is a top 100 analyst with an average return of
Williams-Sonoma has an analyst consensus of Hold, with a price target consensus of $136.79, implying a 17.1% upside from current levels. In a report issued on November 8, Wedbush also downgraded the stock to Hold with a $110.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Kohl’s (KSS)
In a report issued on November 17, Mark Altschwager from Robert W. Baird maintained a Buy rating on Kohl’s, with a price target of $35.00. The company’s shares closed last Friday at $30.98, close to its 52-week low of $24.61.
According to TipRanks.com, Altschwager is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Kohl’s with a $29.88 average price target, representing a -6.6% downside. In a report issued on November 9, Deutsche Bank also maintained a Buy rating on the stock with a $34.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on WSM:
- Analysts Offer Insights on Technology Companies: Keysight Technologies (KEYS), Computer Programs and Systems (CPSI) and PTC (PTC)
- Analysts Offer Insights on Industrial Goods Companies: Lennox International (LII), Dada Nexus (DADA) and APi Group (APG)
- Analysts Offer Insights on Healthcare Companies: Atreca (BCEL), Apellis Pharmaceuticals (APLS) and BeiGene (BGNE)
- Udemy Inc (UDMY) Receives a Buy from Robert W. Baird
- Robert W. Baird Sticks to Its Buy Rating for Leap Therapeutics (LPTX)